The global perennial allergic rhinitis drug market is anticipated to grow at a significant CAGR of 4.0% during the forecast period 2023-2029. The increased awareness of allergic responses around the globe is likely to fuel the growth of the perennial allergic rhinitis market. Additionally, the high quality of drugs and nasal sprays supplied by manufacturers for the treatment of chronic allergic rhinitis is predicted to fuel the growth of the market.
For instance, in October 2021, Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. signed a agreement with Marinomed Biotech AG, whereby the company would gain the rights for the development, manufacture, and commercialization of Budesolv in China which is an indicated for allergic rhinitis. The signing of the license agreement will further expand the company’s product line and enhance Luoxin's competitive edge in the area of respiratory diseases. Further, in September 2021, Hikma Pharmaceuticals PLC announced the signing of an exclusive US license agreement with FAES Farma S.A. to commercialise Bilastine tablets, a non-sedating second-generation antihistamine molecule for the treatment of allergic rhinitis and urticaria.
To Request a Sample of our Report on Perennial Allergic Rhinitis Drug Market: https://www.omrglobal.com/request-sample/perennial-allergic-rhinitis-drug-market
Market Coverage
- The market number available for – 2022-2029
- Base year- 2022
- Forecast period- 2023-2029
Segment Covered-
- By Type
- By Application
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape - including, GlaxoSmithKline PLC, Sanofi SA, Merck & Co. inc., Pfizer Inc., Novartis International AG, among others.
Perennial Allergic Rhinitis Drug Market Report Segment
By Type
- Antihistamines
- Asapiprant
- APC-3000
- Bilastine
- Others
By Application
- Hospitals
- Clinics
- Others
A full Report of Perennial Allergic Rhinitis Drug Market is Available @ https://www.omrglobal.com/industry-reports/perennial-allergic-rhinitis-drug-market
Perennial Allergic Rhinitis Drug Market Report Segment by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East and Africa
Company Profiles
- AstraZeneca PLC
- Boehringer-Ingelhiem International GmbH
- Faes Farma SA
- GlaxoSmithKline PLC
- Glenmark Pharmaceuticals Ltd.
- Hisamitsu Pharmaceuticals Co. Inc.
- Johnson & Johnson Services Ltd.
- Merck & Co. Inc.
- Novartis International AG
- Pfizer Inc.
- Sanofi SA
- Shandong Luoxin Pharmaceutical Group Stock co., ltd.
- Teva Pharmaceutical Industries Ltd.
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/perennial-allergic-rhinitis-drug-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404